In this webinar, Rico Buchli, PhD, presents how next-generation soluble HLA peptide discovery platforms can optimize immunotherapy R&D by providing a framework for target identification, validation, and de-risking across oncology, infectious disease, and autoimmunity.

Human leukocyte antigen (HLA)–presented peptides define one of the most powerful target spaces in immunotherapy. By enabling access to intracellular and mutation-derived antigens, HLA-peptide complexes dramatically expand what can be targeted beyond conventional surface proteins.

Dr. Buchli, Chief Scientist at HLA Protein Technologies, will share how HLA-peptide workflows help teams select targets with higher confidence, reduce offtarget risk, and de-risk programs earlier, with practical examples spanning oncology, infectious disease, and autoimmunity. Participants will connect HLA-peptide target evidence to multiple T-cell–directed therapeutic modalities, such as CAR-Ts, T-cell engagers, and vaccines. You will also leave with a clearer framework for building an HLA-peptide target strategy, what “good” looks like for validation, and where these tools accelerate go/no-go decisions.

Key Topics:

• How HLA-peptide complexes unlock access to intracellular and neoantigen targets


• Strategies for peptide target discovery, validation, and epitope mapping to improve target prioritization


• Approaches to generating fit-for-purpose HLA–peptide reagents to accelerate immunotherapy R&D


• How soluble HLA tools de-risk T-cell–directed therapeutic modality programs